SCHEMBL3010684

SCHEMBL3010684

O=S(=O)(c1ccc(Br)cc1Cl)N1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.42
HSD11B1 P28845 2/20 0.41
LPAR1 Q92633 1/20 0.39
LPAR2 Q9HBW0 1/20 0.39
TSHR P16473 3/20 0.38
HTT P42858 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
AR P10275 1/20 0.36
EPHX2 P34913 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015282 0.94 TRPV4 (0.46) TRPV4HSD11B1LPAR1LPAR2TSHR
SCHEMBL3647788 0.89 ALDH1A1 (0.39) TSHRHTTGAAMEN1KMT2A
SCHEMBL3008531 0.89 TRPV4 (0.40) TRPV4HSD11B1LPAR1LPAR2TSHR
SCHEMBL3014669 0.89 ALDH1A1 (0.44) TRPV4HSD11B1TSHRKDM2BGAA
SCHEMBL3010912 0.88 POLB (0.46) HTTGAAMEN1PKMKMT2A
SCHEMBL3012761 0.87 GAA (0.49) TSHRHTTGAAMEN1KMT2A
SCHEMBL3023052 0.87 TRPV4 (0.38) TRPV4HSD11B1LPAR1LPAR2TSHR
SCHEMBL3016167 0.87 CHRM4 (0.44) TRPV4HSD11B1MEN1KMT2APOLB
SCHEMBL3127462 0.87 ALDH1A1 (0.48) TSHRHTTKDM2BGAAPKM
SCHEMBL3006210 0.87 TRPV4 (0.47) TRPV4HSD11B1LPAR1LPAR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885HSD11B1 1034/4885LPAR1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.